AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05333523 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard elective neck irradiation
Description: Patients randomized to the control arm will receive the standard of care, according to (inter)national clinical practice guidelines. This will consist of (chemo)radiotherapy to the primary tumor with standard elective neck irradiation in all patients. No sentinel lymph node biopsy will be performed.
Study NCT06087770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM3321
Description: Intravenous infusion, once a week, 28 days for a dosing cycle
Study NCT06529341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation
Description: HD-tDCS stimulated AD left OFC (2 mA, 20 minutes, cathode electrode placed in the Fp 1 area, and the remaining four positive electrodes placed AF3, AF7, Afz, Fpz, forming a circular 41 focused electric field mode for stimulation, twice a day, 20 minutes interval for 5 days)
Study NCT06529341 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-definition transcranial direct current stimulation pseudo-stimulation control group
Description: The treatment parameters of the electrode were the same as the test group, the stimulation current rose to the same 2 mA current in the test group within 30 seconds, and the pre-stimulation for 1 minute, then gradually to 0 mA.
Study NCT05459415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reducing Excision Margins
Description: Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy
Study NCT05892237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchial artery interventional therapy
Description: After successful anesthesia, right femoral artery puncture was performed by Seldinger method. 5F-Yashrio catheter is chosen to locate the bronchial artery of the diseased side at the level of the thoracic aortotracheal bifurcation. Angiography was performed (Osu 300mg/ml, 3ml/s, total 8ml, 200Psi) to visualize tumor blood supply artery before infusion of chemo+PD-1 inhibitor and embolism.
Study NCT05892237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: Nano-paclitaxel 260 mg/m2, d1, ivgtt, q3w+Cisplatin 75mg/m2, d1, ivgtt,q3w.
Study NCT05892237 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: 60Gy/2Gy/30f
Study NCT05892237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: PD-1 inhibitor (Tirelizumab) 200mg, d1, ivgtt, 30-60min, q3w.
Study NCT05563337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arteriography and renal denervation
Description: Diagnostic renal Arteriography - Randomization - Renal denervation
Study NCT04949243 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioral questionaires
Description: Behavioral surveys and questionaires
Study NCT06575790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple Meal Bolusing
Description: Participants will enter pre-determined numbers for small, medium, or large carbohydrate meals rather than using precise carbohydrate counting
Study NCT05563337 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Arteriography without renal denervation
Description: Diagnostic renal Arteriography - Randomization
Study NCT05696964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing training enhanced with artificial intelligence
Description: The training in motivational interviewing that medical residents will receive will make use of an artificial intelligence measurement tool, Real-time Assessment of Dialogue in Motivational Interviewing (ReadMI), that produces a spectrum of relevant MI metrics.
Study NCT06575790 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate counting
Description: Participants will be instructed to enter accurate carbohydrate counts to the best of their ability for all meals and snacks
Study NCT05385198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VOICE care
Description: I phase:build a relationship with parents and where the Values of the parents and NICU staff is shared.~II phase: discuss with the parents the Opportunities the parents can have to be more involved in the care of their baby.~III phase: Integration of the involvement of the parents in the care of their baby. The experiences of parents need to be shared with the NICU staff. Any raising issue about the involvement of care by the parents can be discussed and see if improvement is needed.~IV phase:Control of the knowledge about the care of their baby before going home and if the parents have any issues which need to be arranged before discharge.~V phase:Evaluation. During this conversation the overall experiences of the parents will be discussed and if there are any further questions related to the care of their baby at home will be explored and discussed.
Study NCT06552117 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: an elastoMRI sequence
Description: Addition of an MRI elasto sequence performed during MRI performed as part of the treatment
Study NCT06405568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Participants will receive a copy of physical activity (PA) recommendations plus a PA motivation package - namely three 20-minute online webinars (explaining PA benefits and how to get started), digitized PA materials (integrating evidence-based behaviour change tools, and a digitized logbook (to track PA).
Study NCT06569394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Broad Spectrum Cannabidiol (bsCBD) 400 mg
Description: Participants in this Arm will take 400 mg of bsCBD daily. Participants will take medication by mouth with food in the morning and evening.
Study NCT06569394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this Arm will take a medically inert placebo. Participants will take medication by mouth with food in the morning and evening.
Study NCT05910944 — intervention group
Intervention type: PROCEDURE
Intervention: Shunt surgery
Description: Shunt surgery according to each local centers routine
Study NCT05859451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tobacco Heating System (THS)
Description: Participant who are not willing to quit cigarette smoking during the study duration will switch from cigarettes to using THS
Study NCT05859451 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking abstinence
Description: Participant who are willing to quit cigarette smoking and will not use any electronic nicotine delivery system during the study duration
Study NCT04927884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Dose: 15 μg/kg subcutaneously (SC)~Frequency: administered on Day 8 of each cycle (every 3 weeks)
Study NCT04927884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1 t-haNK
Description: Dose: \~2 × 10\^9 cells intravenously (IV)~Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks)
Study NCT04927884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-Hziy
Description: Phase 1b:~Dose level 1: Sacituzumab govitecan-hziy (7.5 mg/kg IV) Dose level 2: Sacituzumab govitecan-hziy (10 mg/kg IV) Dose level -1 (if needed): Sacituzumab govitecan-hziy (5.0 mg/kg IV)~Phase 2: Dose based on Phase 1b Recommended Phase 2 Dose (IV)~Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks)
Study NCT04927884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Dose: 25 mg capsules taken twice per day by mouth (PO)~Frequency: to be taken Days 1-15 and 15-19 of each cycle (every 3 weeks)
Study NCT05668741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-522 mRNA therapy
Description: Oral inhalation using nebulizer.
Study NCT05668741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study NCT06673966 — intervention group
Intervention type: OTHER
Intervention: Regular follow-up assessments without intervention.
Description: Participants will receive a 3-month follow-up with clinical information, biological samples, and imaging data collected at baseline, 1st and 3rd months. The baseline assessment will include demographic information, medical history and previous medication use. At baseline and follow-up, patients' physical examination data (height, weight, waist and hip circumference, etc.), clinical symptom assessment scales (PANSS, SANS, SAPS, CDSS, CPSS, CGI, GAF, PSP, and SAS) and MCCB cognitive assessment data, blood and cerebrospinal fluid samples, MRI, and EEG data will be collected. Collection and store of blood and cerebrospinal fluid samples for routine laboratory tests and multi-omics including immunohistology, inflammation-related molecules, single-cell sequencing, extracellular vesicles, and other assays.
Study NCT06673966 — intervention group
Intervention type: OTHER
Intervention: Cross-sectional assessment
Description: Volunteers' physical examination data (height, weight, waist circumference, hip circumference, etc.), scale assessments (SCID, SCL-90, and CPSS) and MCCB cognitive assessment data, blood samples, MRI, and EEG data will be collected. Blood was collected and stored for exploring differences between patients and healthy individuals.
Study NCT05203640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High repetition (HI)
Description: Participants will perform 15 to 20 repetitions of 7 different exercises at 50% of their one repetition maximum
Study NCT05203640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate repetition (MOD)
Description: Participants will perform 8 to 10 repetitions of 7 different exercise at 75-80% of their one repetition maximum
Study NCT04489134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
Study NCT04489134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Administration of a 2 mg dose of LCP-tacro (Envarsus®)
Study NCT05861375 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan
Description: Fibroscan is a non-invasive device that allows liver exploration painlessly, quickly (a few minutes) and with immediate results. A probe placed on the skin generates an elastic wave completely painlessly and the device measures its speed of propagation in the liver. Liver stiffness is calculated from this speed.
Study NCT05306847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab will be given intravenously at a dose of 200mg every 21 days.
Study NCT05306847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.
Study NCT04881344 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser hemorrhoidoplasty
Description: * Under local anesthetic (or general anesthetic if contraindications to local anesthetic),~* A laser optic fiber connected to a diode platform (Leonardo, Biolitec AG, Jena, Germany) will be applied threw a anoscope. After making a 1-mm opening at the external border of hemorrhoid pocket, the fiber will be introduced in the hemorrhoidal tissue. Several pulses, each lasting for 1.2 s, with a 0.6-s pause between pulses, will be delivered to the tissue.~* As a day-case procedure (or short-stay if medical or social factors precluded ambulatory intervention),~* Postoperative care will consist of: normal diet, bulking laxatives, self-irrigation to the anal wound at six times per day and painkiller. Absence for work certificate will be made for 7 days for each patient and they will be told to return to work and normal daily activities as soon as they felt able.
Study NCT04881344 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mucopexy
Description: * Threw an anoscope, the hemorrhoidal cushion will be sutured using a half-circle (size 26) needle with a 2-0 poliglecaprone (Monocryl®, Ethicon, USA). Then, a continuous suture will be performed on the mucosa of the anal canal, and will terminate above the dentate line. The hemorrhoidal artery will be ligated by this suture. Then, the ligation will be tied to realize the hemorrhoidopexy.~* Same anesthetic technique and postoperative care as the intervention group. As a day-case procedure (or short-stay if medical or social factors precluded ambulatory intervention).
Study NCT05030649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart glasses
Description: The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
Study NCT05030649 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
Study NCT05252715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine
Description: Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 meningococcal polysaccharide combined with tetanus toxoid.
Study NCT05252715 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal A and C Polysaccharide Conjugate Vaccine
Description: Single intramuscular dose contains 10 µg each of Serogroup A and C meningococcal polysaccharide combined with tetanus toxoid.
Study NCT04486261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity strength training
Description: The high-intensity strength training protocol will consist of 2 training sessions per week. The first two weeks will be familiarisation training, where each exercise will be performed in three sets of 10 repetitions at an intensity of 15 repetitions maximum (RM). At week three each session will consist of 3 sets of each exercise corresponding to 10 RM, which will be kept for the remaining part of training intervention. The weights for each exercise will be adjusted throughout the intervention period, so the training load will correspond to 10 RM for each exercise in the entire intervention period.
Study NCT05868135 — intervention group
Intervention type: BEHAVIORAL
Intervention: eMeistring
Description: Initial face-to-face visit, eight/nine sessions/modules of therapist guided ICBT, final face-to-face visit
Study NCT04627688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Participants will be advised to eat only during a selected window of 8 hours, and no later than 4pm, with no advice on nutrition quality, quantity or caloric intake. The intervention will include no medication, no medical device, and will last for 2 weeks prior to surgery.
Study NCT04627688 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dietary advices
Description: Participants will be given standard dietary advices, as recommended by the international nutrition guidelines, and thus are not different from common clinical practice.
Study NCT03503279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath MAC® Video Laryngoscope
Description: McGrath MAC® Video Laryngoscope have been developed to secure the airway and improve the management of difficult intubation. McGrath MAC® is a self-contained VL with a single-use blade; its structure is similar to the ML, but without the channel that guides the tube and a mounted LCD screen on the handle that is connected to a miniature camera with a light source at the tip of the blade, allowing the clinicians to directly observe surrounding anatomical airway structures during a tracheal intubation
Study NCT04650074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LIDOCAINE 20 mg
Description: 4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute.
Study NCT04650074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIDOCAINE 20 mg + KETAMINE 20 mg
Description: 4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 20 mg Ketamine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute.
Study NCT04650074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIDOCAINE 20 mg + KETAMINE 40 mg
Description: 4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 40 mg Ketamine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute
Study NCT06508086 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser ablation technique in the treatment of pilonidal sinus
Description: group (A) will include patients with pilonidal sinus disease who will be operated by sinus tract ablation procedure using 1470 nm Diode laser
Study NCT06508086 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Karydakis technique in the treatment of pilonidal sinus
Description: group (B) will include patients with pilonidal sinus disease who will be operated by Karydakis technique
Study NCT06508255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Time-Restricted Eating
Description: Eat between 8:00 and 16:00 for 2 weeks
Study NCT06508255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late Time-Restricted Eating
Description: Eat between 13:00 and 21:00 for 2 weeks
Study NCT05720598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Node Assessment
Description: The SN assessment will be conducted similarly to the method proposed by Märkl et al. All LNs will be stored in a -80 °C freezer, immediately after retrieval. Within 1 to 3 days, each LN will be individually measured and weighed. Small LNs (\<5 mm in short diameter) will be bisected, and half of the node will be processed for histological evaluation while the remaining half will be used for OSNA analysis. For intermediate-sized LNs (5-10 mm), a middle slice of about 2 mm thickness will be cut out for the histology, and the remaining parts of the node will be processed by OSNA. In large LNs (>10 mm), at least two slices will be cut out for histology, and the remaining parts of the node will be analyzed by OSNA.
Study NCT05720598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Staging laparoscopy
Description: Pneumoperitoneum (10-12mmHg) will be obtained with Veress needle or 10mm trocar after minilaparotomy. Peritoneal cavity will be thoroughly assessed after insertion of two additional trocars. In cases of macroscopic dissemination, peritoneal cancer index (PCI) will be determined. After switching the optical camera into near-infrared / indocyanine green fluorescence mode, the primary tumor will be visualized, followed by assessment and possible dissection of sentinel lymph node with a high-energy device. The lymph node will be retrieved with a sterile bag, and the area of dissection will be marked with a clip. Trocars will be removed under visual assistance, and the pneumoperitoneum will be released through trocars in order to prevent port-site metastases.
Study NCT05720598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastroscopy with indocyanine green (ICG) injection
Description: Patients will undergo gastroscopy one day prior to staging laparoscopy. The ICG powder contains 0.125 mg/ml. Two milliliters of ICG (0.125mg/ml) solution is injected in the submucosa with into four peritumoral sites, 0.5 ml for each site.
Study NCT04918862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: 210 patients were enrolled, divided into two groups \[Granisetron 1 mg: 105 patients received 1mg granisetron, Granisetron 3 mg: 105 patients received 3mg granisetron\]. The two groups were compared in demographic characteristics (age, gender, weight, and height), hemodynamic parameters (MAP and HR), and duration of surgery
Study NCT06328972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: systemic therapy
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time. Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time. Direct feeding training: with powdered milk, once a day, 5 days a week.